Bruker shares jump 13% after Q3 profit beat, cut revenue forecast

Bruker (BRKR) shares rose 13.0% in regular-session trading as of 3:59 p.m. ET, from a regular-session close of $56.50.

Bruker (BRKR) cut its fiscal 2026 revenue forecast on Nov. 4, even as third-quarter non-GAAP earnings topped estimates. The company sells scientific instruments and analytical and diagnostic solutions for life science research, according to its press release.

Revenue for the quarter was $874.0 million, up 1.6% from $860.5 million a year earlier and below the $886.2 million consensus estimate. Organic revenue rose 0.7%, according to the press release.

The company posted a GAAP loss of 81 cents per share, compared with a loss of 41 cents a year earlier. Non-GAAP earnings, which exclude items such as impairments and restructuring costs, were 56 cents per share, beating the 43 cents consensus estimate.

Here's how the company did:

• Revenue: $874.0 million vs. $860.5 million a year earlier, against an estimate of $886.2 million
• Non-GAAP EPS: 56 cents vs. 45 cents a year earlier, against an estimate of 43 cents
• GAAP loss per share: 81 cents vs. 41 cents a year earlier
• Non-GAAP operating margin: 16.3% vs. 12.3% a year earlier

Segment results

Bruker Scientific Instruments revenue was $793.9 million, up 0.8%, with organic revenue down 0.4%. Revenue at Bruker Energy & Supercon Technologies, or BEST, rose 11.2% to $82.1 million.

Effective July 1, 2026, the company reorganized its reportable segments into BSI Biosystems, BSI Microbiology and Infection Diagnostics, BSI NANO and BEST. Prior-period figures were recast to match.

For the first nine months, revenue was $2.54 billion, up 3.1% from $2.46 billion, and non-GAAP EPS was $1.36 against $1.23 a year earlier.

Charges and loss

The company booked a goodwill impairment charge of $174.5 million in the quarter, against $96.5 million a year earlier. The GAAP operating loss was $91.0 million, compared with $51.8 million in the third quarter of 2025.

Net income swung from a loss of $59.6 million in the third quarter of 2025 to a profit of $26.0 million in the fourth quarter of 2025, according to its SEC filings.

2026 guidance

Bruker now expects fiscal 2026 revenue of $3.52 billion to $3.56 billion, down from the $3.54 billion to $3.57 billion range it gave on Aug. 4. Reported revenue growth is now 2.5% to 3.5%, from 3% to 4% previously.

The company now expects currency to be neutral to revenue, from an earlier tailwind of 0.5%. Its non-GAAP EPS forecast of $2.10 to $2.15, an increase of 15% to 17% from $1.83 in fiscal 2025, is unchanged.

Organic revenue growth is still expected to be 1% to 2%, and M&A revenue growth about 1.5%. The guidance uses exchange rates as of Sept. 30, 2026.

President and CEO Frank H. Laukien said, “we see strengthening demand in most of our end markets.” He added: “We expect revenue growth acceleration, continued margin expansion and double-digit EPS growth in FY27.”